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Abstract Circulating tumor cells (CTCs) are impor-
tant targets for treatment and critical surrogate markers
when evaluating cancer prognosis and therapeutic
response. A sensitive methodology for detecting CTCs
in gastric cancer (GC) patients is needed. In this study
we demonstrate a device for enrichment and cultivation
of CTCs. In total, 22 patients with GC, all candidates for
surgery, were enrolled in the study. Peripheral blood
samples were collected before surgery, and patients
were re-evaluated within operation and divided into two
groups: resectable and non-resectable GC. A new size-
based separation test for enrichment and cultivation of
CTCs was used (MetaCell). In addition to cytomor-
phological analysis, gene expression of tumor associat-
ed genes (Cytokeratin-18, Cytokeratin-19, Cytokeratin-
20, Cytokeratin-7, EPCAM, MUC1, HER2, EGFR) and
of leukocyte markers (e.g. CD45, CD68) was tested in
enriched CTC fractions. CTCs were detected in 59 % of
the patients studied (n = 13/22). CTCs were detected in
seven patients of the resection group (7/10, 70 %) and
six of the non-resectable group (6/12, 50 %). Enrich-
ment of the viable CTCs allowed subsequent successful
cultivation in vitro. The cytomorphological charac-
terization of the CTCs was a prerequisite of random
gene expression testing in CTC-positive samples. In
CTC-positive samples gene expression of cytokeratin
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18 and 19 was elevated in comparison to the whole
blood gene expression analysis. CTCs were found to be
present in both resectable and non-resectable gastric
cancer patients. The size-based separation platform for
CTCs may be used for in vitro cultivation, as well as in
subsequent molecular analysis if desired. The sensitivity
of CTC-detection could be enhanced by the combina-
tion of cytomorphological and molecular analysis.
Keywords Gastric cancer  Circulating tumor cells 
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Introduction
Metastatic dissemination is an important prognostic
factor for patients with gastro-intestinal cancer. Exact
staging is crucial to determine appropriate multimodal
therapeutic strategies. The current staging method for
gastric cancer (GC) is based on the staging system of
the International Union against cancer Tumor-Node-
Metastasis (TNM), in which the degree of tumor
penetration (pT) and nodal status (pN) are the two
main prognostic indicators. Early stage patients are
considered for surgery. However, approximately 50 %
of GC patients suffer from tumor relapses even after
radical surgery (Marrelli et al. 2005).
Many research groups have focused on the identi-
fication of new potential biomarkers and novel tests,
yet their specificity and sensitivity in a clinical setting
frequently go reported. Recently, in advanced GC,
measurement of HER2-expression is being recom-
mended when selecting patients for treatment with
Trastuzumab (Duffy et al. 2013). Circulating Tumor
Cells (CTCs) and disseminated tumor cells (DTCs)
could be rare events of primary tumor progression,
which could be used for identification of cancer
recurrence or progression risk. The methodology for
CTC-detection in gastrointestinal cancer has been
recently reviewed elsewhere (Kin et al. 2013). The
development of new isolation platforms for CTCs is
well supported by the need for new predictive markers
in clinical treatment.
The real number of CTCs analyzed in peripheral
blood (PB) in gastrointestinal cancer (colorectal
cancer, GC, oesophageal cancer) is low compared
with other malignancies such a breast and prostate
cancer. The absolute (median) numbers in metastatic
colorectal carcinoma (mCRC) are reported as 1–2
CTCs/7.5 mL of blood in mCRC, 3–5 CTCs/7.5 mL
of blood in metastatic prostate cancer, and 6–7 CTCs/
7.5 mL of blood in metastatic breast cancer (Negin
and Cohen 2010; Hiraiwa et al. 2008; Moreno et al.
2001; Cristofanilli et al. 2012).
Follow-up studies in GC patients suggest that CTC-
positive cases with an increased burden of CTCs were
associated with a poorer prognosis than CTC-negative
patients, and the situation was similar for DTCs (Wang
et al. 2009). Both localized and metastatic GC can
shed a detectable concentration of CTCs into the
blood. The presence of CTCs in the circulation
indicates a high risk of tumor recurrence as well as
unfavourable clinical outcomes, even for early GC
(Zhang and Ge 2013).
The prognostic use of CTCs in GC has been
reported in several studies (Arigami et al. 2011; Saad
et al. 2010; Pituch-Noworolska et al. 2007; Yeh et al.
1998; Koga et al. 2008; Illert et al. 2005; Uen et al.
2006). For GC, the presence of CTC and tumor
markers (e.g. EpCAM/CK8/CK18/C19) seems prog-
nostically the most relevant (Hiraiwa et al. 2008;
Matsusaka et al. 2010). Based on the data analyzed,
detection of CTCs may provide a useful non-invasive
method for prognosis, as well as a means of confirming
a GC diagnosis.
We have developed an easy and highly sensitive
methodology for detecting CTCs in GC patients,
namely the MetaCell platform. In this study we




To date, 22 patients with diagnosed GC have been
enrolled in the study. All patients had GC localized
within 5 cm of the gastro-oesophageal junction, and
were candidates for surgery. The patients’ details are
shown in Table 1.
Peripheral blood was collected prior to surgery. For
each patient approximately 8 mL of venous blood was
drawn from the antecubital veins and placed into
S-Monovette tubes (Sarstedt AG & Co., Nu¨mbrecht,
Germany) containing 1.6 mg EDTA/ml blood as an
anticoagulant. The samples were processed at room
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temperature using an isolation procedure completed
within 24 h of the blood draw.
The ethics committees of all participating univer-
sities and hospitals approved the study protocol
according to the Declaration of Helsinki. All patients
also provided written consent.
CTC enrichment and culture
A new size-based separation method for viable CTC-
enrichment from unclotted Peripheral blood (PB) was
recently introduced (MetaCell, MetaCell s.r.o., Os-
trava, Czech Republic). The process is based on the
filtration of PB through porous polycarbonate mem-
brane (pores of 8 lm diameter, MetaCell s.r.o.,
Ostrava, Czech Republic). Successive blood transfer
into the filtration tube in several steps is preferred, to
prevent blood clotting on the membrane filter. The PB
filter flow is supported naturally by capillary action of
the absorbent material touching the membrane filter.
Afterwards, the membrane filter, which is kept in a
plastic ring, is transferred into the 6-well cultivation
plate; RPMI medium (Sigma-Aldrich, Munich, Ger-
many) is added to the filter top and CTCs are cultured
on the membrane in vitro, under standard cancer cell
culture conditions (37 C and 5 % atmospheric CO2, )
and observed by inverted microscope. Alternatively,
viable CTCs may be observed under a fluorescence
microscope applying vital nuclear stain (NucBlueTM,
Life Technologies, Bleiswijk, Netherlands) and/or
vital cytoplasmic stain (CelltrackerTM, Life Technolo-
gies, Bleiswijk, Netherlands). The CTCs are grown in
an FBS (Sigma-Aldrich, Germany) enriched RPMI
medium (10 %) for a minimum of 14 days and are
analyzed by means of histochemistry (May-Gru¨nwald
staining (Bio-Optica, Milan, Italy) and immunohisto-
chemistry using the tumor specific antibodies to
determine the cell origin (mouse monoclonal anti-
cytokeratin peptide 18-FITC antibody (Sigma), DAPI
(Sigma), Prolong Gold Antifade Reagent (Life Tech-
nologies, Carlsbad, CA, USA).
Next, the enriched CTC fraction can be transferred
from the membrane and cultured directly on a plastic
surface or microscope slide. Microscope slide cultur-
ing is preferred if immunohistochemistry/im-
munofluorescence analysis is planned. If an
intermediate CTCs-analysis is needed, the CTC-
fraction is transferred in PBS (1.5 mL) to the cytospin
slide. The slide is then dried for 24 h and analyzed by
immunohistochemistry.
Additionally, to confirm the origin of the cells on
the separation membrane, the CTC-gene expression
analysis was performed in parallel with the immuno-
histochemistry. The cell fraction enriched on the
membrane without in vitro culturing was assigned as
‘‘virgin’’ CTCs. The reported gene expression analysis
was performed for virgin CTCs (see Fig. 1). For
proceeding with an in vitro culture of these cells, we
analyzed the gene expression of the cells captured (or
grown) on the membrane (so called membrane frac-
tion) as well as the fraction of cells that were able to
overgrow the membrane and set up a new cell culture
on the bottom of the cultivation plastic (see Fig. 1,
‘‘bottom fraction’’). The gene expression of the tumor-
associated markers in the CTC-enriched fractions was
then compared with the gene expression of these
markers in the whole blood RNA.
Cytomorphological analysis
Stained membranes were examined using light mi-
croscopy in two steps: (1) screening at 920 magnifi-
cation to locate cells; (2) observation at 940–960
magnification for detailed cytomorphological analy-
sis. Isolated cells and/or clusters of cells of interest
Table 1 Patients characteristics (22 patients in total, median
age 68,75 years)
T stage Patients (N) CTC positive (N) %
T1 3 1 33.3
T2 1 1 100
T3 8 5 62.5
T4 10 5 50
N stage
N0 3 1 33.3
N1 8 3 37.5
N2 6 4 66.67
N3 5 4 80
M stage
M0 17 10 58.8
M1 5 2 40
Disease stage
I 3 1 33.3
II 4 2 50
III 10 7 70
IV 5 2 40
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(whether immunostained or not) were selected,
digitized, and examined by an experienced researcher
and/or pathologist. CTCs were defined as cells
presenting all the following criteria: (1) nuclear size
C10 lm); (2) irregular nuclear contour; (3) presence
of visible cytoplasm; (4) high nucleus-to-cytoplasm
ratio; (5) prominent nucleoli; (6) proliferation activity;
(7) formation of 3D cell layers.
Gene expression analysis
For GC patients where CTC-presence was confirmed
cytomorphologically (n = 10), gene expression ana-
lysis was subsequently performed. Gene expression
analysis is best done in parallel with immunohisto-
chemistry, in order to provide evidence of the
epithelial origin of the captured CTCs. Gene expres-
sion of tumor associated genes (Cytokeratin-18,
Cytokeratin-19, Cytokeratin-20, Cytokeratin-7,
EPCAM, MUC1, HER2, EGFR) was tested, as was
that of leukocyte markers (e.g. CD45, CD68), with
endogenous control provided by the beta-actin gene.
The gene expression of the CTCs captured on the
membrane is compared to the gene expression of the
tumor markers in the whole blood and between the
‘‘membrane fraction’’ and ‘‘bottom fraction’’ (see
Fig. 1). The cells on the membrane were lysed by
RLT-buffer with b-mercaptoethanol (Qiagen—
CEEMED, Praha, Czech Republic), RNA was then
isolated using RNeasy Mini Kit (Qiagen). The RNA
from whole blood was isolated with a modified
protocol. The protocol is including the erythrocyte-
lysing step. The quality/concentration of RNA was
measured by NanoDrop (ThermoScientific). As there
are only a few hundred cells on the membrane, the
median concentration of RNA was quite low
(5–10 ng/ll). For cDNA production we used the High
Capacity cDNA Reverse Transcription Kit (Life
Technologies). For Gene expression analysis we
employed Taqman chemistry including Taqman
MGB—probes for all the above-mentioned genes
(Life Technologies). (A list of Taqman probes we
employed is given in the supplementary material.) The
gene expression results report the CTC positivity in
case of an increased gene expression of tumor-
associated genes in CTC-fractions in comparison to
the whole blood RNA.
Results
We report successful CTC isolation in 59 % of GC
patients (n = 13/22). The CTC cell morphology and
immunohistochemistry is shown in Fig. 2. The cap-
tured cells were stained positively for CK18. The
CK18 molecule has generally been accepted as a
marker of cancer with an epithelial origin (Fareed et al.
2012). A summary of the CTC positivity statistics is
given in Table 1; Figs. 3 and 4. Overall, the size-based
filtration approach enabled the capture of viable CTCs.
Fig. 1 Gene expression
analysis of the enriched
CTC-fractions
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We proved the viability of the CTCs by culturing the
CTC cells in vitro, and confirming with further
analysis (e.g. immunohistochemical or molecular). If
desired the DNA and RNA molecules may be used for
further mutational and gene expression testing. We do
not have a recent survival analysis of the group of
patients tested, but thanks to the data obtained, we are
able characterize CTC dissemination in the pre-
defined patient sub-groups based on disease stage
(see Fig. 3b, c). It is of interest that 70 % of patients
with resectable GC were CTC-positive, while patients
deemed unresectable were only 50 % positive. The
CTC-positivity rates in resectable/non-resectable GC
patients and other GC-subgroups were compared by
Chi square testing. No significant difference was
found comparing resectable and non-resectable group
of patients in our study (P = 0.0623).
Although the study group of GC patients was
relatively small, the CTC-positive rates correlate with
the disease stage as well as lymph node involvement.
Samples from GC patients where CTC-presence was
proven cytomorphologically were eligible for subse-
quent gene expression analysis. The gene expression
results can serve as additional evidence of epithelial
cell-origin alongside the immunohistochemistry.
Analyzing the molecular character of the CTCs we
may conclude that in our GC CTCs samples, an
increased cytokeratin-18 and cytokeratin-19
Fig. 2 a CTC with two nuclei captured and cultured on a
membrane filter with visualized filter pores. b Nucleus coun-
terstained with DAPI. c CTC captured and cultured on a
membrane filter, incubated with CK-18-FITC antibody with an
unspecifically visualized micronucleus, with nucleus of ir-
regular shape counterstained with DAPI
Fig. 3 a Gastric cancer disease stage and CTC–positivity ratio.
b T stage in Gastric cancer and CTC positivity. c N stage in
Gastric cancer and CTC positivity
Fig. 4 Resectability of gastric cancer and CTCs positivity
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expression was seen in all of the tested samples, with
some redundant EpCAM and MUC1 expression as
well. In none of the tested samples was cytokeratin-7
found. Gastric tumor histology confirmed the expres-
sion of HER2 and EGFR. In all the samples tested
CD45 and CD68 expression was reported, but the
expression level was much lower in the enriched CTC-
samples on the membrane or after in vitro culture. We
can report that the mRNA transcripts of cytokeratins
and other possible epithelial markers are more abun-
dant in the enriched CTC-fractions than in the whole
blood. These facts combined with the cytomorpho-
logical analysis seem to be reasonable evidence for
CTC-presence and successful CTC-detection. A com-
bination of vital cell stain and subsequent gene
expression analysis of the stained cells on the mem-
brane could give an immediate answer as to what kind
of the cells have been isolated.
Discussion
The detection of malignant cells in blood has been
established for many years (Engell 1955). More recent
studies have demonstrated the malignant nature of
CTCs (Fehm et al. 2002). In the early days of CTC
research several groups attempted to identify and
detect CTCs in PB but only by reverse transcription
polymerase chain reaction (RT-PCR). In their study
Soeth et al. (1997) noted that GC patients found
positive for CK 20 mRNA (17 % of 30 patients) had
significantly shorter survival times than those who
tested negative. Miyazono et al. (2001) examined the
presence of CTCs in blood samples from 57 GC
patients. After density gradient separation of CTCs,
CEA-specific real-time RT-PCR was performed and
correlated with the time course during the surgical
procedure and the onset/advent of hepatic tumor
recurrence. Interestingly, the authors were able to
show that CEA-mRNA could not be detected in a
control group of healthy volunteers or in 15 patients
with benign disease. In contrast, a total of 21 GC
patients (36.8 %) were positive for CTCs as detected
by CEA-specific RT-PCR and positive rates correlated
with depth of tumor invasion. In addition, the authors
found that GC patients with high levels of CEA were
more likely to develop systemic disease.
In our study we saw higher CTC-positive rates than
previously reported. But this may be caused by the
enrolling in our study of patients with more advanced
stages of GC. Another possibility is that the combi-
nation of cytomorphological and molecular analysis
could be more sensitive for CTC detection in GC cases
than previously reported methods. The big advantage
of our approach is the ability to obtain biological
material, namely CTCs cells, which are suitable for
further downstream molecular analysis, e.g. gene
expression profiling.
With the introduction of immunomagnetic separa-
tion techniques, not only detection but also quantifi-
cation of CTCs becomes possible (Allard et al. 2004).
Matsusaka et al. (2010) showed that the number of
CTCs before and during treatment is an independent
prognostic and predictive marker in GC patients.
Patients with more than 4 CTCs identified at 2 and
4-weeks after start of chemotherapy had a shorter
median progression-free survival (PFS), (1.4, 1.4
months, respectively) than those with\4 CTCs (4.9,
5.0 months, respectively). Patients with more than 4
CTCs at 2 and 4-weeks after initialization of
chemotherapy had shorter median overall survival
(OS), (3.5, 4.0 months, respectively) than those with
\4 CTCs (11.7, 11.4 months, respectively).This study
was performed using immunomagnetic platform with
magnetic beads labelled with antibodies to GC cells
that express specific cells surface antigens (EpCAM,
CK8, CK18, CK19 and CD45). All antibody-based
enrichment techniques may be limited by the possible
loss of cells without the expression of epithelial
antigens as metastatic cells undergo epithelial-mes-
enchymal transition (EMT). Changes in the cytoskele-
ton of epithelial cells such as the regression of
cytokeratin can be observed (Sun et al. 2011). Several
size-based filtration devices seek to overcome this
limitation of lower sensitivity of antibody methods
(Zheng et al. 2010). Similarly, we have shown a
successful filtration-based approach for CTC detec-
tion, finding that 59 % of GC patients in the study
were CTC positive.
Uenosono et al. (2013) published a study covering
251 patients with resectable and non-resectable GC
(Uenosono et al. 2013). CTCs were detected in 16
patients (10.8 %) of the resection group and 62
patients (60.2 %) of the non-resectable group. The
OS rate for the entire cohort was significantly lower in
patients with CTCs than in those without them
(P \ 0.0001). A significantly smaller number of
patients took part in our study, but a very high
1100 Cytotechnology (2016) 68:1095–1102
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proportion of our ‘‘resectable’’ group were CTC
positive (70 %). The significant difference between
Uenosono and colleague’s study and ours was the
CTC-detection platform. Uenosono employed an
epithelial marker-dependent methodology
(CellSearch), whereas we used an antibody-inde-
pendent technology platform (MetaCell) that identi-
fies CTCs by size. The choice of detection platform is
important because of Epitelial-Mesenchymal Trans-
duction (EMT), a widely reported prerequisite for
metastasis, which may lead to underestimation of CTC
numbers. The inadequacy of the EpCAM-based
immunomagnetic capture method compared with the
size-based filtration method has been reported in
several studies for different cancers (Farace et al.
2011; Krebs et al. 2012).
The advantage of the filtration method that we used
is not only a higher detection rate but the ability to
separate viable cancer cells. Enriched viable CTCs can
be cultured for downstream testing as shown by gene-
expression analysis or for single-cell analysis to detect
CTC heterogeneity. For the first time in the study of
GC the reported platform enables separation of viable
CTCs and their subsequent cultivation.
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